A phase II study of ZD1839 [gefitinib] and radiation in patients with squamous cell carcinoma of the skin.
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2014
At a glance
- Drugs Gefitinib (Primary)
- Indications Skin cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Jan 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Nov 2011 Planned end date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.